Azenta Inc (AZTA)vsNovartis AG ADR (NVS)
AZTA
Azenta Inc
$23.13
-4.58%
HEALTHCARE · Cap: $1.07B
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 9408% more annual revenue ($56.58B vs $595.03M). NVS leads profitability with a 23.9% profit margin vs -10.1%. AZTA appears more attractively valued with a PEG of 0.53. AZTA earns a higher WallStSmart Score of 57/100 (C).
AZTA
Buy57
out of 100
Grade: C
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+42.6%
Fair Value
$53.08
Current Price
$23.13
$29.95 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 8778.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
0.8% revenue growth
Smaller company, higher risk/reward
ROE of 1.5% — below average capital efficiency
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZTA
The strongest argument for AZTA centers on Price/Book, EPS Growth, Debt/Equity. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : AZTA
The primary concerns for AZTA are P/E Ratio, Revenue Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
AZTA profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
AZTA carries more volatility with a beta of 1.47 — expect wider price swings.
AZTA is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
AZTA scores higher overall (57/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Azenta Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Azenta Inc. is a premier provider of sample management solutions and life science tools, dedicated to enhancing laboratory efficiencies for the biotechnology and pharmaceutical industries. By leveraging innovative automated solutions, comprehensive biorepository services, and advanced storage technologies, the company enables clients to accelerate drug discovery while adhering to stringent regulatory requirements. With a strong emphasis on cutting-edge technology and strategic partnerships, Azenta is well-positioned to seize growth opportunities in the expanding global life sciences market. Its commitment to advancing scientific research through sophisticated products further solidifies its competitive advantage in biobanking and sample management.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?